- Home
- NFJ vs NVCR Comparison
NFJ vs NVCR Comparison
Compare NFJ & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- NVCR
- Stock Information
- Founded
- NFJ 2005
- NVCR 2000
- Country
- NFJ United States
- NVCR Switzerland
- Employees
- NFJ N/A
- NVCR N/A
- Industry
- NFJ Finance: Consumer Services
- NVCR Medical/Dental Instruments
- Sector
- NFJ Finance
- NVCR Health Care
- Exchange
- NFJ Nasdaq
- NVCR Nasdaq
- Market Cap
- NFJ 1.2B
- NVCR 1.4B
- IPO Year
- NFJ N/A
- NVCR 2015
- Fundamental
- Price
- NFJ $12.50
- NVCR $11.32
- Analyst Decision
- NFJ
- NVCR Buy
- Analyst Count
- NFJ 0
- NVCR 7
- Target Price
- NFJ N/A
- NVCR $28.79
- AVG Volume (30 Days)
- NFJ 223.5K
- NVCR 1.8M
- Earning Date
- NFJ 01-01-0001
- NVCR 07-24-2025
- Dividend Yield
- NFJ 9.01%
- NVCR N/A
- EPS Growth
- NFJ N/A
- NVCR N/A
- EPS
- NFJ N/A
- NVCR N/A
- Revenue
- NFJ N/A
- NVCR $630,160,000.00
- Revenue This Year
- NFJ N/A
- NVCR $6.15
- Revenue Next Year
- NFJ N/A
- NVCR $7.35
- P/E Ratio
- NFJ N/A
- NVCR N/A
- Revenue Growth
- NFJ N/A
- NVCR 14.58
- 52 Week Low
- NFJ $10.45
- NVCR $10.91
- 52 Week High
- NFJ $12.86
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- NFJ 46.63
- NVCR 25.05
- Support Level
- NFJ $12.64
- NVCR $10.91
- Resistance Level
- NFJ $12.90
- NVCR $12.38
- Average True Range (ATR)
- NFJ 0.15
- NVCR 0.93
- MACD
- NFJ -0.03
- NVCR -0.49
- Stochastic Oscillator
- NFJ 14.89
- NVCR 6.13
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.